A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520775-81-00

Acronym

ZP1848-25009

Enrollment

Registered

2025-11-26

Start date

2025-12-23

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short Bowel Syndrome

Brief summary

TEAEs from baseline (Visit 1) to the safety follow-up visit

Detailed description

Change in prescribed weekly PS volume from baseline to Month 24/EOT

Interventions

DRUGGlepaglutide 20.0 mg/mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
TEAEs from baseline (Visit 1) to the safety follow-up visit	—

Secondary

Measure	Time frame
Change in prescribed weekly PS volume from baseline to Month 24/EOT	—

Countries

Belgium, France, Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026